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Hemoglobin, the protein component of red blood cells,
functions by combining with oxygen in the lungs and there¬
after releasing oxygen to the body tissues. More than one
hundred variants of hemoglobin are known and the greater
number of these involve a defect in the beta chains. Most
variants differ from the normal hemoglobin by an exchange of
one type of amino acid residue for another. Hemoglobin S is
one of these variants and is used in limited quantities in
this research.
The blood cells of hemoglobin S differ physically from
the round shaped cells of hemoglobin A by their characteris¬
tic crescent and sickled shape. Emmel (1917) coined the
term "sickle cell" which led to the now commonly known
disease "sickle cell anemia." In the latter 19^0's, the
basis for these "sickled" cells became known and work began
to prevent and eliminate the sickling process. Pauling
et al. (19^9) suggested that the sickling behavior might be
due to the presence of a chemically different type of
hemoglobin molecule than the normal hemoglobin A which
would on deoxygenation aggregate into rods and thereby
twist the red blood cell out of shape. Pauling (1952)
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suggested that hemoglobin S might aggregate or stack to¬
gether in long chains because of surface conformations. In
addition it was shown that each of four heme groups in the
hemoglobin A molecule is associated with a polypeptide
chain. Two types of polypeptide chains exist; the alpha
chain, containing l4l amino acid residues and the beta
chain, containing l46. Hemoglobin S molecule differs from
hemoglobin A by the substitution of valine for glutamic
acid at the sixth position in each of the beta chains.
This study was chosen with the underlying causes of
sickle cell anemia in mind, namely the hemoglobin S mole¬
cule. Hemoglobin A was used to screen reagents saving
hemoglobin S for the most promising reagents. Hemoglobin A
behaves in a similar way as hemoglobin S. Both aggregate
to some extent under solution conditions in the cell.
Sophianoupoulos (1973) noted that urea (the drug now used
in treating sickle cell anemia) dissociated hemoglobin A
at high concentrations and that aggregates of hemoglobin A
are broken into smaller components thus providing a more
fluid movement of the molecules. This was observed by the
intense effect shown upon reduced viscosity of highly con¬
centrated hemoglobin A whereby urea nearly halved the
reduced viscosity of concentrated hemoglobin A. Hemo¬
globin S would likewise dissociate in the presence of
chemicals that would attack the defective hydrophobic
bond in the molecule. Therefore, hemoglobin A was used
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as a model for hemoglobin S in screening the effectiveness
of reagents for treatment of sickle cell anemia.
Many clinical symptoms of sickle cell anemia are
attributed to an increase in blood viscosity as well as
improper blood circulation caused by the distorted red
cells. After a review of the literature, it was found that
one relatively unexplored approach to determine and corre¬
late other molecular characteristics of hemoglobin A and S
is that of viscometry. With this in mind, and the problem
of increased blood viscosity in sickle cell anemia, the
reason for this research work was founded. The objectives
of this study were to determine (l) the effect of urea,
malonamide, propionamide, succinamide, KCl and oxamate in
disaggregating hemoglobin, (2) the effects of these
chemicals on the reduced viscosity of hemoglobin, and (3)
the effects of certain conditions on the reduced viscosity
of hemoglobin. The reduced viscosity in this study is the
specific viscosity divided by protein concentration.
CHAPTER II
REVIEW OF LITERATURE
Sickle cell anemia was discovered as a molecular
disease relating to a defect in the hemoglobin molecule.
Pauling et al. (19^9) suggested that the process of
sickling may be intimately associated with the state and
nature of hemoglobin within the erythrocyte. Sickled
erythrocytes, in which the hemoglobin is combined with
oxygen or carbon monoxide, have biconcave disks differing
from the normal donut shaped red cells. The hemoglobin
appears to be uniformly distributed and randomly oriented
within both types of cells. Removal of oxygen and carbon
monoxide transforms hemoglobin to the uncombined state and
causes the sickled cells to undergo sickling. Within the
sickled cell, it appears to aggregate into one or more loci
and the cell membrane collapses. Oxygen and carbon
monoxide reverse these conditions. Thus, Pauling et al.
(19*^9) were the first to recognize and establish with
experimental evidence that sickle cell anemia is a molec¬
ular disease and that the molecular structural anomaly of
hemoglobin S is under genetic control.
The abnormal S molecule differs from the normal S by
an amino acid substitution in each beta chain. This
U
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chemical difference does not explain the behavior of
hemoglobin S nor the sickling mechanism. Murayama (196T)
presented precision scale models of hemoglobin S which
indicate that the genetic substitution of valine for
glutamic acid at the sixth position in the two beta chains
allows the formation of an intramolecular hydrophobic bond
This changes the conformation in such a way as to allow
molecular stacking. Subjection of hemoglobin S to tempera
ture change, high hydrostatic pressure and propane are
consistent with the presence of such a bond.
From a steric point of view, according to Murayama
(1967), it appears that a hydrophobic intramolecular bond
in hemoglobin S could form between the terminal residue,
valyl, of the beta chain and the genetically substituted
sixth residue, valyl, in the same chain. No bond of this
type forms in normal hemoglobin. When the valyl-valyl
bonds form in the beta chains, the molecule changes in sur
face conformation so as to present a projecting "key" type
structure. The intramolecular bonds would also allow a
cycle to form from the first - C=0 to the fourth NH2 by
hydrophobic bonding. As Murayama indicates in the model,
the key should fit into a complementary site in the alpha
chain of an adjacent molecule. Murayama (I967) also
believes that the change in conformation allows aggrega¬
tion of molecules in long rods or filaments as well as
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molecular stacking. He noted, that sickled erythrocytes
orient in a magnetic field with polarized light as if the
cells contain longitudinal fibrillar structures aligned
in situ. Normal human erythrocytes show no orientation in
the magnetic field. In support of Murayama's belief of the
existence of filaments. White (1968) believes the degree of
erythrocyte distortion is related to the amount of sickled
hemoglobin converted into rod and the extent to which the
rods become associated in parallel bundles. The formation
of a monofilament as a result of stacking would also be
consistent with the behavior of sickled erythrocyte in
relation to oxygen. The fact that sickling takes place
upon deoxygenation suggests that the complementarity
between the data chain and the adjacent alpha chain is lost
upon oxygenation.
White (1968) found glutarylaldehyde to be an excellent
fixative for preserving hemoglobin S iji situ and in pro¬
moting the sickling phenomenon. The results of his experi¬
ments indicate that dense rods similar to those found in
hemoglobin A do occur in the cytoplasm of sickled erythro¬
cytes and parallel orientation of these rods appears
instrumental in crumpling erythrocytes containing hemo¬
globin S. White (1968) goes on to indicate that changes
in the external form which occur during incubation of
sickled cells with 1% glutarylaldehyde are identical to
those which develop in deoxygenated samples of sickled
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blood. Internally, filaments and rods, which form in cells
exposed to glutarylaldehyde alone, are identical to struc¬
tures preserved in cells which have been deoxygenated with
sodium bisulfite and reduced oxygen tension. It would
appear that glutarylaldehyde promotes sickling in the same
manner as agents which convert oxyhemoglobin to reduced
hemoglobin. Previous studies by Harris (1959) establish
that glutarylaldehyde is an active cross-linking agent that
combines with amino groups of proteins. By cross-linking
polypeptide chains, it increases the molecular weight and
reduces solubility without causing a loss of molecular con¬
figuration. Conversion of sickle cell hemoglobin to a
polymerized state on exposure to glutarylaldehyde represents
a change in molecular configuration. It is possible that
the advancing wave of fixative causes hemoglobin to give
up oxygen prior to reaction of glutarylaldehyde with poly¬
peptide chains. Glutarylaldehyde is a dialdehyde and may
serve as a reducing agent, but no evidence is present to
indicate that it acts like other reducing agents on hemo¬
globin S.
Along with the advent of modern methods and techniques
came the discovery of certain agents, chemicals and condi¬
tions that cause hemoglobin S molecule to behave normally
or nearly so. Rieder (1970) observed that formation of
inclusion bodies upon exposure of red blood cells to redox
dyes and increased precipitation of hemoglobin solutions
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upon heating to 50 C were typical of unstable hemoglobin.
Rieder also suggests that erythrocyte inclusion body forma¬
tion appears to have some common basis with heat denatura-
tion and alkali denaturation of hemoglobin.
Cyanide is said to reduce the precipitate of hemo¬
globin after twenty hours of exposure to a temperature of
50 C, (Rieder, 19T0). The ability of ligands to stabilize
hemoglobin during severe, prolonged heat stress was demon¬
strated by the effect of carbon dioxide and cyanide on hemo¬
globin solution heated to 65 C for two and one half hours.
The same results were obtained in the study of alkali de¬
naturation of methemoglobin in presence and absence of cya¬
nide. Ligands are said to be important since they affect
binding of heme to globin on stabilization of the hemoglobin
molecule. Rieder further contends that the stabilizing
effect of cyanide on normal hemoglobin heated to 50 C
extend also to hemoglobin H. Monomeric alpha chains were
denatured after five minutes of heating with cyanide in the
buffer. This suggests that some sort of interchain inter¬
action may be strengthened by addition of cyanide to
methemoglobin. Binding of cyanide to only alpha chains
strengthens the entire complex and prevents precipitation
after prolonged heating. Steinhardt et al. (1963) pos¬
tulated that stabilization can occur by combination of
ligand with a single heme of each hemoglobin dimer.
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Binding of cyanide, according to Rieder (1970), is
associated with a decrease in ionic character and an in¬
crease in covalent bonds between histidine and heme iron
and between iron atom and the four pyrolle rings of
porphyrin. The porphyrin group is drawn closer to the pro¬
tein portion of the molecule and iron moves to a position
closer to the plane of porphyrin. Such changes could result
in tighter binding of heme to globin. Steinhardt et al.
(1963) suggested that the stabilizing effect of cyanide may
be due to a loss of plus charge on iron of ferric hemoglobin
upon binding the ligand. The charged iron atom without
ligand, together with attached porphyrin, is thought to be
situated further towards the outer portion of the hemoglobin
molecule and thus more exposed to the solvent medium of high
dielectric constant. As a result, a reduction in ionic
strength of the medium increases the protein stability.
Carbon dioxide and oxygen, both environmental condi¬
tions, are known to affect hemoglobin A and S to varying
degrees and in different ways. When either the alpha or
beta chain terminal amino group of hemoglobin is blocked,
the oxygen linked effect of carbon dioxide is reduced by
one half (Kilmartin and Rossi-Bernardi, I969).
According to Salhany et al. (1971), deoxygenation
kinetics of purified isolated adult hemoglobin A and S
equilibrated in the absence of carbon dioxide and in the
presence of 37 millimeters of mercury at 23 C demonstrate
10
that the rate of deoxygenation is lower for hemoglobin S
as compared to hemoglobin A. It was found that carbon
dioxide (via carbamate formation) increased the rate of
deoxygenation for both type protein. However, the rate of
deoxygenation was increased only half as much for hemoglobin
S. This condition is analogous to the effect of carbon
dioxide on hemoglobin where the beta chain N-terminal amino
group is blocked. These results suggest that the N-terminal
ends of the beta chains of hemoglobin S are inactivated as
oxygen linked groups and as a result, when carbamate is
formed, a lesser effect is observed on oxygen release. The
inactivation of these ends can be accounted for by
Murayama*s hypotheses which proposes that the A1 beta valine
is hydrophobically bonded to the A3 beta valine on hemo¬
globin S (Murayama, I967). Such bonding would lead to a
stabilization of that end and possibly account for the re¬
duced effect of carbon dioxide on hemoglobin.
In addition to environmental conditions, certain
chemicals also have an effect on hemoglobin A and S.
Harris (1959) states that during hypoxia, gelling and
tactoid formation of hemoglobin S take place and deform
the red cell membrane into the sickled shape. Murayama
(1968) suggests that this owes its origin to hydrophobic
bonding between the N-terminal valine residue and the sixth
valine residue. The valyl-valyl bond fits a complementary
site of the alpha chain of an adjacent molecule. Hemo-
11
globin S aligns linearly and by head to tail stacking
produces a hemoglobin monofilament.
Motulsky and Stamatoyannopoulos (1968) relate clinical
severity of sickling to increased blood viscosity during
deoxygenation which is dependent on hemoglobin S concentra¬
tion. In the presence of other hemoglobin in the red cell,
modification of sickling can occur. Harris (1950) and
Charache and Conley (1964) agree that sickled red cells also
cause an increase in blood viscosity. Increased viscosity
slows blood flow in small blood vessels causing more hypoxia
and further sickling. Sickle cells interlock and form
masses in vessels causing small vessel obstruction with
symptoms of pain in the abdomen and around the joints (Diggs,
1965). Motulsky and Stamatoyannopoulos (I968) suggest that
acidosis further increases sickling and may be a factor in
post anesthetic states. Splenic circulation slows and
leads to splenic infarction. Pulmonary infarcts can occur
during post anesthetic states. Death and acute red cell
sequestration may occur during general anesthesia. Various
infarctive processes may be more common in nonanemic sick¬
ling states, since viscosity on sickling increases with the
square of the hematocrit.
Motulsky and Stamatoyannopoulos (I968) contend that
sickled cells orient with their long axis perpendicular to
magnetic lines of force while normal cells do not. Since
only the beta chains move closer together on oxygenation.
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complementarity would be lost during oxygenation and result
in desickling.
Propane prevents the hydrophobic valyl-valyl bonding by
forming hydrophobic bonds with isopropyl groups of valyl
side chains and blocks intermolecular valyl-valyl inter¬
actions (Motulsky and Stamatoyannopoulos, 1968). The drug
is too toxic, however, for ^ vivo use. Kosower et al.
(1967) suggested that introduction of glutamic acid residues
in hemoglobin S might diminish gelling and increase its
solubility. Results were achieved by coupling the N-
carboxyl anhydride of glutamic acid to the N-terminal end
of the beta chain of hemoglobin S molecule. Other ap¬
proaches, such as induction of methemoglobin (Beutler and
Mikus, 1961) which prevents sickling also interferes with
physiologic functions of hemoglobin. Good results for
phenothiazines (Hathorn and Lewis, I966) were not confirmed
(Pearson and Noyes, 1967). Agents such as steroids appear
to interfere with sickling by red cell membrane interaction,
but are less promising to use therapeutically than those
based on molecular manipulations (Isaacs and Hayhoe , I967).
Studies by Bromberg and Andrade (l97l) indicate that
the cause of the decrease in oxygen affinity of sickle cells
is due in part to their decrease in 2, 3-diphosphoglycerate
content and to an increase in cell organic phosphate levels.
An additional effect is attributed to intracellular poly¬
merization of deoxgenated hemoglobin S molecule.
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Sickle cell anemia is an inherited condition charac¬
terized by "hemolysis, acute, painful episodic crises and
progressive damage by infarction to multiple organs as the
spleen, kidneys and lungs" (McCurdy, 1972). Song (1971)
believes that sickle cell anemia is a hemolytic anemia
resulting from the shortened life span of erythrocytes and
that "sickled cells tend to impede the circulation by en¬
twining in the smaller veins and venous side of the capil¬
lary bed." McCurdy and Mahmood (l97l) suggest that sickled
cells are made rigid by intracellular gelling of hemoglobin
S and may logjam in small blood vessels, leading to throm¬
bosis and infarction. Life expectancy is decreased.
Individuals who are homozygous for the "sickling gene" will
demonstrate sickle cell anemia and those who are hetero¬
zygous will show a similar but less severe disease. The
major cause of disability is the painful crises which accom¬
pany the disorder.
An advancement in treating the sickle cell crises over
fluid and electrolyte replacement and transfusion is the use
of urea. Initial experiments with phenothiazines, antico¬
agulants and intravenous dextran prove valueless. Ponder
and Ponder (195^) used urea in aqueous solutions in differ¬
ent concentrations and observed that it successfully re¬
versed sickling in intact erythrocytes. Nalbandian and
Evans (l97l) used urea to reverse sickling in red blood
cells after exposure to sodium metabisulfite. However,
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within thirty minutes extensive hemolysis occurred. This led
to the use of urea in sugar solutions as a blocking and
desickling agent without producing hemolysis.
Murayama (1967» 1968) showed that concentrated, deoxy-
genated hemoglobin S in the gel state can be dispersed by
lowering the temperature of the system, increasing the
hydrostatic pressure and by introducing short-chain ali¬
phatic hydrocarbons such as propane under low pressure. On
the basis of this and other evidence, Murayama (1967)
developed a molecular hypothesis for the mechanism of
sickling which implies that a chemical method that prevents
or destroys the formation and perpetuation of the pathologic
intertetrameric hydrophobic bonds leading to the sickling
event may be of therapeutic value in preventing or reversing
sickling. Such a chemotherapeutic agent should be water
soluble, nontoxic, easily diffusible through body fluids,
cross the red cell membrane without injurious sequelae
and be able to break hydrophobic bonds to a modest degree
without denaturing the tertiary or the quaternary structure
of hemoglobin molecule. Bruning and Holtzer (196I) showed
that urea could break hydrophobic bonds in addition to its
well known action of breaking hydrogen bonds as originally
proposed by Mirsky and Pauling (1936). Nalbandian et al.
(1971) demonstrated with optical microscopy and scanning
electron microscopy that red blood cells (sickled by
Na^SgO^) showed an essentially complete reversal within
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ten minutes after addition of IM UIS (urea in sugar solu¬
tion). Transmission electron microscopy showed that fila¬
ments induced hy Na^S^O^ disappeared after exposure to UIS.
Barnhart et al. (1970) demonstrated desickling by intra¬
venous urea in invert sugar with scanning electron micros¬
copy. Sickled cells were reduced in twelve hours UIS treat¬
ment .
Nalbandian et al. (I97l) believe that UIS is an effec¬
tive chemical desickling agent because the urea molecule
requires less energy to form new hydrophobic bonds with
hydrogen groups of the substituted valine residues at the
number six position of both beta chains. It is also
believed that urea forms hydrophobic bonds with unidentified
amino acid residues in the reciprocal combining sites of the
alpha globins in the interacting tetramers. Thus, the
effect of urea is to induce steric alterations in the con¬
figuration of the hemoglobin S tetramer and consequently,
steric hindrance to tetramer-tetramer interaction.
According to Nalbandian et al. (1971)j the therapeutic
elevation of blood urea levels is not the metabolic equiva¬
lent of the physiologic dislocation of clinical uremia.
In clinical uremia and sickle cell crises, adverse physio¬
logic factors may inhibit and override the desickling
action of urea. At first glance, one may expect that the
proposed treatment of sickle cell crises by infusion of
UIS should be contraindicated in those patients with renal
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insufficiency, but an argument to the contrary can be made.
Merrill et al. (1953) demonstrated by dialysis against a
high urea gradient that such patients became asymptomatic
while retaining their original urea blood levels.
Nalbandian et al. (1971) suggested that a patient in sickle
cell crises with renal insufficiency be dialyzed against a
high urea gradient. As the removal of the noxious metab¬
olites is achieved by dialysis, the endogenously retained
urea at an appropriate blood level may be expected to be
effective in terminating the crises.
Murayama (1967) demonstrated that intact homozygous S
cells sickled by any of three physiologic methods (nitro¬
gen, helium or carbon dioxide) and subsequently desickled by
urea in sugar solution could again sickle by adding urease
and incubating at 35 C. Murayama further noted that hemo¬
globin S erythrocytes, previously carbamylated with potas¬
sium cyanate, were not visibly affected by subsequent incu¬
bation with urease.
From experiments by Nalbandian et al. (1971)j it is
noted that a therapeutic lag of several hours may be antici¬
pated in clinical trials between the onset of infusion of
UIS and termination of pain and/or hemolysis. This lag is
believed to be due to the slow rate of diffusion to tissue
physiologically compromised by sickling in the vascular sys¬
tem. Until urea is sufficiently concentrated at effective
levels within erythrocytes in such regions and until the
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majority of the hemoglobin S are combined with urea in a
molar ratio of 1:^1 or more, no reversal of sickling in the
obstructed circulation and no clinical improvement should
be expected. On the basis of the unsuccessfully treated
cases, the interval of therapeutic lag appears to range
from 8-10 or 12 hours.
Nalbandian et al. (19T1) presented preliminary reports
in which they established specific clinical protocol for
intravenous, oral and prophylatic use of urea as a therapeu
tic treatment for sickle cell crisis. Nalbandian further
suggested oral and prophylatic methods as more advantageous
than intravenous methods. Lipp et al. (1972) contradicted
this by finding no apparent effect from oral urea adminis¬
tration to patients with sickle cell anemia. This result
indicated that the only significant difference was a rise
in blood urea nitrogen (BUN) level. Two possible expla¬
nations are that the course of therapy was too short and
the serum levels too low to reverse sickling.
Nalbandian (l97l) designated at least four mechanisms
that may be suggested for urea's mode of action. First,
urea may form a clathrate around the hydrophobic substi¬
tuted number six valine residue in each beta S globin chain
or urea may combine (urea to valine) at such points on the
hemoglobin S tetramer. By such reactions the conformation
of the hemoglobin S molecule is altered and sickling is
prevented or reversed by steric hindrance. Second, because
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urea has an electric dipole moment of 4.6 compared to a
value of 1.8 for the water molecule, it is possible that the
urea molecule may disperse and randomize the precisely
structured formation and maintenance of the pathologic
hydrophobic bond for polymerizing the molecule of hemoglobin
S. Third, both of the above mechanisms may be involved. On
the basis of available information, these views can only be
presented as hypothetical and considerable study of the prob¬
lem by physical chemists will be required before the mecha¬
nisms are understood. A fourth possible explanation for the
molecular action of urea has been suggested by Cerami and
Manning (1971). Urea ionizes to a small extent in aqueous
solutions to form cyanate ions and these ions may carbamylate
the N-terminal valine residue (the natural number one valine
residue and not the substituted number six valine) in about
25^ of the beta S globin chains. Nalbandian (1972) believes
that carbamylation with hemoglobin S does occur in the
presence of potassium cyanate. However, when the modes of
action of urea and potassium cyanate are compared it is
clear that these two compounds act in a separate and unre¬
lated manner at the molecular level. Nalbandian's experi¬
ments with urease indicate that the urea molecule per se
mediates the desickling event. Apparently, therapy with
potassium cyanate will be useful in the prophylaxis of
sickle cell disease, but this can be of no value in the
management and early termination of acute sickle cell
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crisis.
The recent use of urea prompted Cerami and Manning
(1971) to investigate the possibility that cyanate, vhich
is in equilibrium with urea in solution, might prevent the
sickling of erythrocytes. They found that high concentra¬
tions of urea (IM) were needed to prevent reversible
sickling of 80% of the cells, whereas O.Ol-O.lOM of
potassium cyanate irreversibly inhibit sickling to the same
extent. The prevention of sickling is a function of the
amount of cyanate incorporated into acid precipitable pro¬
tein.
Cerami (1972) estimated that 30% of the carbon dioxide
produced in the tissues is carried to the lungs via car-
bamino compounds formed with the amino terminal valine of
the hemoglobin molecules. Cerami also states that deoxygen-
ated sickled cells incorporate cyanate and sickling is
reversed. Oxygenation results in normal morphology of J5%
of these cells. Upon deoxygenation these cells remain
normal. Potassium cyanate was also found to be an effective
inhibitor of the gelling of deoxygenated hemoglobin S.
Cerami and Manning (1971) found that a molar solution
of urea at 37 C and at pH J.k contains, at equilibrium,
5 millimoles of cyanate. The time necessary for the
attainment of equilibrium concentration of cyanate from
urea depends upon the concentration of urea, pH, tempera¬
ture of dissolution of the urea and the temperature of
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storage of the solution. Therefore, solutions of urea pre¬
pared for infusion may contain different amounts of cyanate.
The concentration of cyanate necessary to have an effect on
sickling, ^ vivo, would he less than that, ^ vitro, if a
cumulative reaction over a longer period of time is assumed.
The extent to which cyanate might have been responsible for
the effectiveness of urea treatment in the crisis phase was
not determined.
Since the presence of carbamyl groups on the NH^ ter¬
minal valine residue of hemoglobin prevents the formation of
carbamino compounds, Cerami and Manning (1971) tested
whether blocking of some of the NHg-terminal residue was
detrimental, vivo. Mice were injected once daily with
sublethal doses of KCNO with no ill effects. After twenty
injections, the mice erythrocytes contained an average of
1:6 carbamyl group per hemoglobin molecule. Thus, the pres¬
ence of several carbamyl groups on hemoglobin does not seem
to interfere seriously with the physiology of the red blood
cell. This suggests that cyanate may be used to prevent
erythrocyte sickling ^n vivo.
de Furia et al. (1972) noted that the reaction of
cyanate with hemoglobin S was shown to inhibit sickling and
to prolong erythrocyte survival i^ vivo. Similar car-
bamylation reactions could occur with other cellular
enzymes and proteins and alter their physiologic function,
de Furia further shows that the carbamylation of one of the
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four NH^ terminal valine residues of both alpha and beta
chains of hemoglobin does not lead to a lowered pH of the
blood. The slight reduction in red cell carbon dioxide
level appears to be compensated for by an increase in the
amount of plasma bicarbonate. The oxygen affinity of cells
which are carbamylated at one of the four NHg terminal
valines of hemoglobin responds to changes in pH as do con¬
trol cells. de Furia et al. (1972) also noted that the
carbamylation of normal, sickled and DPG-depleted erythro¬
cytes, increase oxygen affinity of the cells. This increase
may be a result of stabilization of the oxy-conformation of
the hemoglobin molecule since the levels of ATP and DPG are
not affected by carbamylation.
Perutz and Mazzarella (1969) showed with x-ray crystal¬
lography that amino terminal valine residues form intra¬
molecular salt bridges when hemoglobin is in the deoxygen-
ated conformation. The presence of the uncharged carbamyl
group on the amino terminal valine residue may interfere
with this salt bridge and stabilize the oxy-conformation.
The stabilization of the oxy-conformation by carbamylation
may also explain the anti-sickling effect of cyanate.
Since carbamylated deoxygenated hemoglobin S may remain in
the oxy-conformation form, these molecules may interfere
with the aggregation of other non-carbamylated hemoglobin
S molecules. This hypothesis is consistent with the
finding that some patients require as little as 0.1
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carbamyl group per hemoglobin tetramer to inhibit sickling.
de Furia et al. (1972) noted that increased oxygen
affinity of carbamyl sickled cells would lead to decreased
oxygen delivery and tissue hypoxia. However, since carbamy-
lation decreases sickling and prolongs the life span of
sickle cells, the red cell mass and oxygen delivery should
increase. In addition, the cells should be able to increase
their DPG concentration and counteract the effects of an
increased oxygen affinity.
Experimental studies by Kraus and Kraus (1971) led them
to observe that carbamyl phosphate incubated with whole
blood iji_ vitro inhibits the sickling phenomenon in deoxygen-
ated erythrocytes from patients with sickle cell anemia.
The effective ratio of carbamyl P (phosphate) is U-8 moles
per hemoglobin molecule. A greater effect in the prevention
of sickling is apparent when carbamyl P is incubated with
deoxygenated erythrocytes than with the oxygenated ones.
Carbamyl P utilized in the body for biosynthesis of urea,
arginine and the pyrimidine ring, is present in the
dianionic form in aqueous solution at blood pH. Allen and
Jones (196U) suggest that the carbamyl P dianion decomposes
through a monomolecular elimination of cyanic acid. Cyanic
acid is then ionized to the stable cyanate ion.
Kraus and Kraus (1971) observed that the variation
between the effect of carbamyl P on blood used within 2k
hours of drawing sample and that stored at U C for U8
23
hours suggest that aging of the red cells may deplete or
change the concentration of a molecule which is involved in
the carbamyl P effect. In the aged erythrocyte the preven¬
tion of sickling is enhanced twofold. Also since the
carbamyl P effect is more marked in the deoxygenated cell
and since it takes longer to achieve an effect upon the
oxyerythrocyte, it would appear that there is a difference
related to the conformation of hemoglobin in the oxygenated
molecule as opposed to the deoxygenated molecule. Benesch
and Benesch (1970) established that there is a phosphate
binding site in hemoglobin occupied by 2, 3-diphospho-
glycerate (DPG) which binds with deoxygenated hemoglobin and
not with oxygenated hemoglobin. Kraus and Kraus (l97l)
suggest that when oxygen is released from the hemoglobin
molecule, the carbamyl P may compete with DPG for the site
within the tetramer. Located in a position within a hemo¬
globin molecule, the carbamyl P undergoes a monomolecular
elimination decomposing to the stable cyanate ion in situ.
The cyanate ion is now in a position to carbamylate the NHg
terminal valine residue of the hemoglobin chain. This may
be the mechanism by which carbamyl P inhibits the sickling
in deoxygenated hemoglobin S erythrocyte. Charache et al.
(1970) have shown that DPG concentrations of whole blood
are higher in sickle cell anemic persons than in normal
persons and that there is variation in DPG values between
persons. Bunn and Briehl (1970) reported a decrease in
2k
ATP and DPG in stored "blood. The decrease in DPG may "be a
factor in enhancing the effect of carbamyl P on blood stored
for 48 hours.
Reynolds (l9Tl) reports that in spite of previous
negative reports and lack of objective data, it appears that
hyperbaric oxygen may occasionally be a useful form of
symptomatic therapy for painful sickle cell crisis.
By far, oxygen is found to be the most effective agent




Whole "blood preserved in EDTA was obtained from Grady
and Emory University Hospitals. All other reagents were
analytical grade or best grade available. Double glass-
distilled water was used in all experiments. Hemoglobin A,
S and trait S were isolated as described for the gel test by
Nalbandian (l97l)* A desired amount of blood was washed
three times with 0.9^ isotonic saline and in some cases
isotonic sucrose and then centrifuged at 3,000 rpm for
fifteen minutes between washings. After the final wash,
double distilled water in an amount equal to one fourth the
volume of packed cells was added. A drop of toluene was
added to prevent bacterial invasion. This blood solution
was centrifuged again for twenty minutes at 3,600 rpm in the
cold room and the supernatant containing hemoglobin was
removed with a pipette.
Hemoglobin concentration was determined by the
cyanmethemoglobin method as described by Todd (1962). Four
clean cuvettes were each filled with the following solu¬
tions: Tube 1 contained 5 ml of Acuglobin Hemoglobin
Standard; tube 2 contained 2.5 ml of Hemoglobin Standard
and 2.5 ml of Drabkins diluent; tube 3 contained a 1 + 250
25
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dilution of isolated hemoglobin and diluent; and tube k
served as the blank and contained 5 ml of Drabkins diluent.
The optical density of these solutions was measured on a
Beckman quartz spectrophotometer with wave-length set at
5^+0 millimicrons. Hemoglobin concentration (Hbc) was
calculated as follows:
%ds = . %mAs.
ODS ODU
Hbc = ^ds . DF
where ds is the diluted sample of isolated hemoglobin; S
is the whole sample of hemoglobin; uds is the undiluted
sample of isolated hemoglobin; ODS and ODU are the optical
densities of the Hemoglobin Standard and the unknown iso¬
lated hemoglobin and Df is the dilution factor of isolated
hemoglobin mixed with Drabkins diluent.
The desired molar concentration and amount of each
reagent, urea, malonamide, propionamide, succinamide,
potassium chloride and oxamate were prepared based on the
molecular weight of each reagent. The metric and analytical
balances were used in weighing all reagents.
Viscosity measurements were made in an Ostwald
viscometer placed in a 37 C water bath. Preliminary
viscosity experiments with water were carried out prior to
experiments with hemoglobin A, S and trait S. Three
milliliters of hemoglobin was placed into the viscometer
followed by varying amounts of reagent at different
27
intervals. The time in seconds was recorded. Prior to
adding reagents, viscosity measurements of the initial
hemoglobin were determined. The viscosity measurements were
repeated four times and an average calculated. The above
procedures were repeated for hemoglobin A and S. Hemoglobin
and reagent were thoroughly mixed prior to measurements.
Reduced viscosity described here is specific viscosity
divided by protein concentration. It was calculated by
using the following formula:
Reduced Viscosity = JLtJ— . 100
(to)
Hb concentration
where t is the viscosity of hemoglobin in seconds and tQ
is the viscosity of water or other diluent used. The
varying concentrations of reagent and hemoglobin were
calculated following the addition of reagent using the
formula . C2 .
CHAPTER IV
EXPERIMENTAL RESULTS
The effects of several chemicals on reduced viscosity
of hemoglobin are shown in Table 1 and Figures 1 through 3.
Prior to the addition of urea, the reduced viscosity of
hemoglobin is high at 39% hemoglobin concentration, but
decreases as the concentration of urea increases. This can
be seen in Table 1. By comparing the two curves in Figure
1, it can be seen that at high hemoglobin concentration,
there is a decrease in the reduced viscosity of hemoglobin
A. At low hemoglobin concentration, there is a slight
decrease in the reduced viscosity of hemoglobin A. Table 1
shows that potassium chloride has a similar effect as
oxamate in that they both affect the reduced viscosity of
hemoglobin A in the presence and absence of oxamate. It
shows that oxamate decreases the reduced viscosity of
hemoglobin and in the absence of oxamate, hemoglobin is more
viscous and the flow is slower. Table 1 reveals that
malonamide and propionamide have a much less effect on
reduced viscosity of hemoglobin A. Succinamide appears
more effective at higher concentrations. It appears that
malonamide has an insignificant effect on the reduced
viscosity of hemoglobin as seen in Figure 3. One can also
28
TABLE I
REDUCED VISCOSITY OF CONCENTRATED HEMOGLOBIN SOLUTIONS, AND










A 39 0.60 - - 92
A 37.1 0.58 urea 4.70 53
A 33.5 0.52 urea 9.90 30
A 29.7 0.45 urea 11.40 19
A 3it.9 0.54 - - 145
A 33.2 0.52 urea 3.17 132
A 31.2 0.47 urea 2.99 91
A 17.32 0.27 - - 38
A 17.03 0.27 malonamide 0.820 31
A 16.76 0.26 malonamide 0.806 31
A 16.50 0.26 malonamide 0.794 28
A 36 0.56 - - 271
A 35. 0.55 malonamide 0.82 250
A 34.3 0.53 malonamide 2.40 210
A 33.2 0.52 malonamide 3.80 181













A 26.91 0.42 propionamide 0.13 115
A 26.47 0.42 propionamide 0.816 112
A 25.63 0.40 propionamide 1.58 96
A 24.84 0.38 propionamide 1.53 86
A 36 0.56 - - 356
A 34.4 0.54 succinamide 1.6 112
A 33.8 0.52 succinamide 3.12 96
A 32.7 0.51 succinamide 4.5 87
A 24 0.37 - - 2l4
A 23.6 0.36 KCL 0.800 102
A 23.2 0.36 KCL 1.60 65
A 22.85 0.35 KCL 2.40 51
A 24 0.37 - - 199
A 24 0.37 KCL 1.60 97
A 22.9 0.35 KCL 2.40 61
A 36 0.56 - - 358
A 34.8 0.54 KCL 1.60 56
A 33.8 0.52 KCL 3.1 28
A 32.7 0.51 KCL 4.5 21
A 39 0.60 - - 200
A 35.5 0.55 HgO - 185
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Table I (Continued).









A 34.9 0.54 oxamate 0.75 50
A 33.4 0.52 oxamate 1.43 16
A 29.3 0.45 oxamate 6.8 8
A 36 0.56 - - 345
A 34.8 0.541 oxamate 1.60 44
A 33.8 0.52 oxamat e 3.10 24
A 34.9 0.54 - - 165
A 32.7 0.51 oxamate 1.56 4o
A 31.7 0.50 oxamat e 3.30 26
S 12.8 0.22 - - 44
S 12.69 0.22 oxamate 0.86 32
S 12.5 0.22 oxamate 1.25 31
trait S 28.5 0.44 - - 273
trait S 28.03 0.44 oxamate 0.820 100
trait S 27.14 0.42 oxamate 1.63 48
trait S 26.30 0.40 oxamate 1.54 37












trait S 20.70 0.32 oxamate 0.810 89
+bubbled N2
trait S 20.37 0.32 oxamate 0.806 61
*A11 solutions were equilibrated to air composition.
No corrections were made for density differences between
solvent and solution, which would be small for the magnitude
of viscosities reported and used in this research.
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Figure 1. A graph of reduced viscosity as a function of
hemoglobin A concentration at 37 C, in the
absence (open circle) and in the presence
(closed circle) of urea.
ReducedViscosity
3h
Figure 2. A graph of reduced viscosity as a function of
hemoglohin A concentration at 37 C, in the
absence (open circle) and in the presence
(closed circle) of oxamate.











Figure 3. A graph of reduced viscosity as a function
of hemoglobin A concentration at 37 C, in
the absence (open circle) and in the
presence (closed circle) of malonamide.
ReducedViscosity
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see that when 0.0075 M of oxamate is added to 39^ hemoglobin
the reduced viscosity of hemoglobin A is decreased to more
than one half the original value. At 32.'J% hemoglobin,
0.0156 M oxamate decreased the reduced viscosity to half the
original value as seen in Table 1. When the percent hemo¬
globin was low, little or no effect by reagents was observed
and this is seen in Table 1 by the effect of oxamate on
hemoglobin S. The effect of oxamate on trait S hemoglobin
is also shown and appears very effective.
CHAPTER V
DISCUSSION AND CONCLUSIONS
Viscosity studies in this research show that aggregates
of both hemoglobin A and S are formed at high protein con¬
centrations. Hemoglobin S has a greater aggregation ten¬
dency than A. This is demonstrated by the dependence of
specific viscosity on protein concentration. Reduced viscos¬
ity used here is specific viscosity divided by protein con¬
centration. In this study hemoglobin S was more viscous than
A but an average sample of hemoglobin S concentration was
lower than the same sample of A. Hemoglobin A was chosen as
a model for screening reagents which disaggregate hemoglobin
S because of the scarcity of hemoglobin S. Since hemoglobin
A aggregates to a lesser degree than hemoglobin S, any agent
not disaggregating A would not be likely to disaggregate
hemoglobin S. Thus, the scarce hemoglobin S was saved to
test promising reagents. Hemoglobin A, as this study shows,
is aggregated to some degree under the solution conditions
in the cell. Therefore, to have an effective desickling
reagent, it may be sufficient only to decrease the extent
of aggregation to a certain level. In this instance,
oxamate was seen to be very effective in disaggregating
hemoglobin. Potassium chloride also appears to have an
37
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effect on decreasing the reduced viscosity of hemoglobin A.
A higher concentration of potassium chloride appears needed
for an effective decrease in reduced viscosity than the con
centration of oxamate required for the same decrease. The
other reagents, urea, propionamide, malonamide and
succinamide vere also effective hut not to the same extent.
High viscosity is caused hy strong intermolecular
attraction which lowers the free motility of the molecules.
For this reason the viscosity of water, whose molecules are
hound to each other hy hydrogen bonds, is higher than that
of ether or ethanol. Hourowitz (1963) implies that in pro¬
tein solutions the increase in viscosity is caused hy inter
molecular interaction between protein molecules. Viscosity
of different protein solutions do not always behave in a
similar way. Protein solutions such as gelatin are
extremely viscous and others such as ovalbumin or serum
proteins flow more easily even if their concentration is
much higher than gelatin. In my study it was shown that
hemoglobin S is more viscous than A whose concentration,
however, was higher than S.
The molecular conformation of tetramers of hemoglobin
A and S can be compared. The genetic lesion in hemoglobin
S, the beta-6-valyl residue in each beta globin chain,
results in a small tetrahedral protrusion located along the
bottom edge of each tetramer. On hemoglobin A, with
glutamic acid in the beta 6 position, no such hydrophobic
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protrusion occurs. In the deoxygenated state, the heta S
globin chains are displaced laterally and in the presence
of adequate concentration of the sickling cofactor,
hydrophobic bonds are formed between alternate interacting
molecules of hemoglobin S and pairs of cofactor molecules
which lead to helical aggregations or monofilaments. The
monofilaments then aggregate laterally to form six-membered
microcables or superhelices. Eventually, the entire molec¬
ular population within the red cell participates and induces
deformities in the red cell membrane causing the sickled
shape. This does not occur in hemoglobin A because of the
absence of the valine hydrophobic bonds and the sickling
cofactor. The sickling cofactor is a dialyzable, nonprotein,
low molecular weight compound which is essential to the
sickling event. At one "end" of the sickling cofactor
molecule, where it contacts either an alpha globin or a beta
globin hydrophobic residue, a hydrophobic bond is formed.
Upon deoxygenation, the beta globin chains shift centrally
so that the distance is too great for the cofactor molecule
to bridge. Work is still in progress to characterize the
structure, biochemical origin, and other properties of this
dialyzable cofactor, the head-to-tail stacking and aggrega¬
tion of thousands of molecules into long chains lead to a
viscous mass of blood cells. The hydrophobic bond of the
valine molecule offers a position of attachment. For once
the hydrophobic bond is displaced, no mass clumping or
Uo
aggregation of hemoglobin tetramers occur.
In this study, hemoglobin S was noted to be of low con¬
centration and as a result, on occasions, it was difficult
to obtain very effective data. Therefore, hemoglobin A,
being of high concentration served well in this capacity as
a screening agent. To my knowledge, no viscosity measure¬
ments of over 29/J hemoglobin S concentration have been
recorded. Figs. 1 through 3, in the experimental results,
show that there is an increase in reduced viscosity higher
than 15^ hemoglobin concentration. The effect of reduced
viscosity on hemoglobin concentrations lower than this
showed little or no change. Hemoglobin was isolated from
packed cells after adding water one fourth the volume of
packed cells. In this instance the concentration of hemo¬
globin would be slightly less than the actual hemoglobin
concentration in the cell. Thus, the effect on the higher
hemoglobin concentrations are more relevant to the condi¬
tions in the red blood cell.
It is known that urea liquifies hemoglobin S gels
(Nalbandian, 1971)> and as shown in Fig. 1, urea decreases
the reduced viscosity of hemoglobin A. In Table 1, it is
observed that at 37% hemoglobin concentration, hemoglobin
A is nearly a gel which is liquified by 0.047 M urea. The
concentration of urea is shown to be proportional to reduced
viscosity which is inversely proportional to hemoglobin A
concentration. In support of this data, it was observed
1^1
that urea does reverse and block sickling (Nalbandian and
Evans, 1971)* They also believe that the reversal of
sickling is possible by breaking the hydrophobic interaction
between beta-6-valyl groups and corresponding complementary
binding sites on the adjacent alpha chains. This inter¬
action is responsible for the formation of tetramer aggre¬
gates. A question has been raised by researchers as to
whether urea or some component of urea is the real desickling
agent. Cerami and Manning (1971) investigated the possibil¬
ity that cyanate, which is in equilibrium with urea in
solution, might prevent sickling. It was found that both
urea and cyanate prevent sickling, although a lower concen¬
tration of cyanate was required. However, urea showed
lesser side effects than pure cyanate. Other reagents are
needed which would cause less side effects.
Table 1 shows that oxamate appears to have more effect
on decreasing the reduced viscosity than urea. At 0.075 M
concentration, oxamate more than decreased the reduced
viscosity to less than half at 3h.9% hemoglobin concentra¬
tions. Its effect on trait S blood presents similar results.
Oxamate, as seen in Table 1, appears to be more effective on
the reduced viscosity of hemoglobin at very low concentra¬
tions as compared to high concentrations of urea required.
Oxamate is believed not to undergo any molecular changes
once added to blood. Oxamate, therefore, appears to be a
promising agent in the desickling phenomenon. In support
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of this Sophianopoulos (1973) has done further work with
oxamate. He has demonstrated hy sedimentation and other
studies that oxamate does appear to disrupt the hydrophobic
bonds of valine and desickle cells.
Even though the measurements found in this study are
accurate, the composition of the hemoglobin solutions are
variable, since lysed red cells were used without further
purification. In addition, the exact hemoglobin composition
of trait S blood was not determined.
The reagents used here appear to have an influence
on reduced viscosity, but in order to determine such effects
in more detail all pertinent parameters such as shifts in
oxygen tension and binding curves as well as the Bohr effect
must be determined and correlated.
It is concluded that urea, potassium chloride and
oxamate cause a decrease in the reduced viscosity of
hemoglobin. This decrease in reduced viscosity may be
needed but it is not a sufficient condition to prevent
sickling. Of all these reagents, it is concluded that
oxamate is the most effective.
It should be emphasized that this study does not
prove that any of these reagents are safe for experimenta¬
tion on humans. Until further work is done and it is
proven so, no such experimentations should be attempted.
Although hemoglobin concentration ^ vitro may be close to





Viscosity studies conducted in this research with
various chemicals show that aggregates of hemoglobin A, S
and the mixture trait S are formed at high protein concen¬
trations. Hemoglobin S molecule has a greater aggregation
tendency than hemoglobin A. This is demonstrated by the
dependence of specific viscosity on protein concentration.
Reduced viscosity is specific viscosity divided by protein
concentration. This study shows that oxamate, urea and
potassium chloride have a great effect on decreasing the
reduced viscosity of hemoglobin as compared to a lesser and
practically no effect of malonamide, propionamide and
succinamide.
It can be said that even though potassium chloride
appears to lower the reduced viscosity of hemoglobin, it
turns out that all salts have this same effect. Potassium
chloride, already present in the cell, would thus have an
effect on desickling. Thus, a reduction in reduced vis¬
cosity does not necessarily imply a desickling ability.
Oxamate, also a salt, has an effect on the reduced viscosity
of hemoglobin. My studies conclude that urea, potassium
chloride and oxamate do cause a decrease in reduced vis-
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cosity of hemoglobin and that this decrease may be necessary
but not a sufficient condition to prevent sickling. Oxamate
seems to be the most promising and further work by
Sophianopoulos (1973) shows that oxamate does desickle cells
and offers a potential of becoming useful in the treatment
of sickle cell anemia.
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